Antiviral Activity of Single‐Dose PRO 140, a CCR5 Monoclonal Antibody, in HIV‐Infected Adults | Zendy

Jeffrey M. Jacobson | Zendy; Michael S. Saag | Zendy; Melanie Thompson | Zendy; Margaret A. Fischl | Zendy; Ralph Liporace | Zendy; Richard C. Reichman | Zendy; Robert Redfield | Zendy; Carl J. Fichtenbaum | Zendy; Barry S. Zingman | Zendy; Mahesh Patel | Zendy; Jose D. Murga | Zendy; Suzanne M. Pemrick | Zendy; Paul D’Ambrosio | Zendy; Marti Michael | Zendy; Hans Kröger | Zendy; Hieu Ly | Zendy; Yakov Rotshteyn | Zendy; Robert G. Buice | Zendy; Stephen Morris | Zendy; Joseph Stavola | Zendy; Paul J. Maddon | Zendy; Alton B. Kremer | Zendy; William C. Olson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antiviral Activity of Single‐Dose PRO 140, a CCR5 Monoclonal Antibody, in HIV‐Infected Adults

Author(s) -

Jeffrey M. Jacobson,

Michael S. Saag,

Melanie Thompson,

Margaret A. Fischl,

Ralph Liporace,

Richard C. Reichman,

Robert Redfield,

Carl J. Fichtenbaum,

Barry S. Zingman,

Mahesh Patel,

Jose D. Murga,

Suzanne M. Pemrick,

Paul D’Ambrosio,

Marti Michael,

Hans Kröger,

Hieu Ly,

Yakov Rotshteyn,

Robert G. Buice,

Stephen Morris,

Joseph Stavola,

Paul J. Maddon,

Alton B. Kremer,

William C. Olson

Publication year - 2008

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/592169

Subject(s) - monoclonal antibody , ccr5 receptor antagonist , virology , chemokine receptor ccr5 , human immunodeficiency virus (hiv) , antibody , chemokine receptor , chemokine , monoclonal , in vitro , virus , viral replication , cc chemokine receptors , immunology , medicine , biology , inflammation , biochemistry

The current goal of human immunodeficiency virus type 1 (HIV-1) therapy is to maximally suppress viral replication. Securing this goal requires new drugs and treatment classes. The chemokine receptor CCR5 provides an entry portal for HIV-1, and PRO 140 is a humanized monoclonal antibody that binds to CCR5 and potently inhibits CCR5-tropic (R5) HIV-1 in vitro.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research